Health Care Select Sector SPDR Fund (XLV) ETF Price, Holdings & News

Technical Score (1D)

BUY

News Sentiment

BULLISH

What's happening to XLV today?

XLV is riding a sharp oncology upswing, anchored by AbbVie’s Phase‑III CERVINO data that just came out 3.4 hours ago, showing a 74 % objective response rate and a 60 % reduction in progression‑or‑death risk, which points to a likely accelerated approval within the next 1–10 trading days. The same day, AbbVie’s $10.9 billion acquisition of Apogee Therapeutics expands its oncology pipeline, reinforcing the sector’s earnings‑growth narrative and providing a buffer against the competitive pressure already eroding rivals’ margins. Johnson & Johnson’s implied 12 % annual revenue growth—well above its 7‑7.6 % guidance—creates re‑pricing risk that could ripple through XLV’s consumer‑health holdings if management fails to narrow the gap, while AbbVie’s etentamig threatens JNJ’s Tecvayli in multiple myeloma, adding second‑order pressure on JNJ’s oncology revenue. Merck’s Keytruda faces a new biosimilar threat from Cipla, raising questions about pricing strategy and the broader competitive pressure in oncology that could erode blockbuster margins. UnitedHealth’s first‑half 2026 results—showing a 1.2 % revenue lift and a 20.5 % EPS jump driven by tighter medical‑cost ratios—support the ETF’s health‑services exposure and hint at margin expansion that could sustain valuation over the next 1–10 trading days. Eli Lilly’s modest 1.25 % contribution from the African launch of Mounjaro signals confidence in the global GLP‑1 market, and its earnings beat with upbeat guidance suggests the core business remains robust, potentially cushioning short‑term volatility in the weight‑loss segment. Across the ETF, the convergence of accelerated regulatory prospects, pipeline expansion, and margin tightening suggests that the next few trading sessions will be dominated by earnings guidance revisions and FDA decisions. Traders should monitor AbbVie’s regulatory update, JNJ’s guidance revisions, and UnitedHealth’s Medicare Advantage enrollment data for signals that will shape XLV’s short‑term earnings trajectory.

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage (Top ETF Holdings)

ETF: XLV

0+ articles

Last updated: February 15, 2026

XLV ETF: Investment Factors

The Health Care Select Sector SPDR Fund (XLV) is structured as an ETF, designed to mirror the performance of a specific healthcare index. This structure allows investors to gain broad exposure to the healthcare sector, encompassing pharmaceuticals, healthcare equipment, and biotechnology firms. The fund's non-diversified nature means it may be more susceptible to the performance of its top holdings, which include significant allocations to Eli Lilly and UnitedHealth Group.

XLV's investment strategy centers on replicating the index by investing at least 95% of its assets in the index's constituent securities. This approach provides targeted exposure to the healthcare sector, making it a tool for investors seeking to capitalize on industry trends. The fund's focus on healthcare providers, biotechnology, and related services offers a diversified approach within the healthcare space, though concentration in top holdings should be considered.

Sector Exposure

XLV provides focused exposure to the healthcare sector, offering a targeted investment vehicle for those bullish on the industry. The fund's holdings span various sub-sectors, including pharmaceuticals, healthcare equipment, and biotechnology. This broad approach allows investors to participate in the growth of the healthcare industry as a whole.

The ETF's structure allows for easy access to a diversified portfolio of healthcare companies. This structure simplifies the process of gaining exposure to a wide range of companies within the healthcare sector. Investors can use XLV to gain exposure to the healthcare sector without the need to select individual stocks.

The fund's holdings are weighted according to the index methodology, which may result in significant allocations to the largest companies within the healthcare sector. This weighting approach can influence the fund's performance, making it sensitive to the financial health of its top holdings.

Holdings Concentration

XLV's portfolio is concentrated in a few key holdings, with Eli Lilly and UnitedHealth Group representing significant portions of the fund. This concentration means that the fund's performance is heavily influenced by the performance of these specific companies. Investors should monitor these top holdings closely.

The top holdings in XLV are primarily large-cap healthcare companies, which can provide stability but also limit the potential for outsized gains from smaller, more volatile stocks. This concentration can lead to a more predictable performance profile. The fund's non-diversified status further emphasizes the importance of understanding the top holdings.

The fund's top holdings are subject to the specific risks associated with each company, including regulatory changes, competitive pressures, and market dynamics. Investors should consider the individual risks of the top holdings when evaluating XLV as an investment option.

Expense Considerations

Information regarding the expense ratio for XLV is not provided in the available data. Investors should seek the expense ratio information from the fund's prospectus or other official documentation. The expense ratio impacts the fund's overall returns.

The expense ratio represents the annual cost of operating the fund, including management fees and other expenses. A higher expense ratio can reduce the net returns for investors. Investors should compare the expense ratio of XLV with similar ETFs.

Understanding the expense ratio is crucial for evaluating the overall cost-effectiveness of the investment. Investors should consider the expense ratio in relation to the fund's performance and investment strategy.

ETF Structure

XLV is an ETF, designed to track the performance of a specific healthcare sector index. This structure allows for intraday trading and provides investors with a liquid way to gain exposure to the healthcare sector. The ETF structure offers diversification benefits.

The fund's structure allows for easy access to a diversified portfolio of healthcare companies. This structure simplifies the process of gaining exposure to a wide range of companies within the healthcare sector. Investors can use XLV to gain exposure to the healthcare sector without the need to select individual stocks.

As an ETF, XLV is subject to market fluctuations and trading costs, which can impact overall returns. Investors should consider these factors when evaluating the fund's suitability for their investment goals.

Trading Liquidity

As an ETF, XLV benefits from intraday trading, providing investors with the flexibility to buy and sell shares throughout the trading day. This liquidity is a key advantage of the ETF structure. The fund's liquidity is generally high.

The fund's liquidity is influenced by the trading volume of the underlying securities and the overall market conditions. High trading volume typically indicates greater liquidity. Investors can easily enter and exit positions.

Investors should consider the bid-ask spread when trading XLV, as wider spreads can increase transaction costs. Monitoring trading volume and spreads can help investors manage trading frictions.

Portfolio Role

XLV can serve as a core holding for investors seeking exposure to the healthcare sector, providing diversification and access to a broad range of companies. The fund can be used to build a diversified portfolio.

The fund can be used to complement other investments, such as growth stocks or international equities, to create a well-rounded portfolio. This approach can help manage overall portfolio risk. Investors can use XLV to gain exposure to the healthcare sector.

Investors should consider their overall investment objectives and risk tolerance when incorporating XLV into their portfolio. The fund's performance should be evaluated in the context of the broader market and economic conditions.

Positioning XLV

Given the fund's focus on the healthcare sector, XLV can be a strategic addition to portfolios seeking sector-specific exposure. Investors should evaluate the fund's top holdings, particularly Eli Lilly and UnitedHealth Group, to understand the primary drivers of its performance. Consider adjusting your XLV allocation based on your outlook for the healthcare industry and the broader market. Regularly review the fund's holdings and performance to ensure alignment with your investment goals.

What Influences XLV?

XLV's performance hinges on the health care sector's outlook, particularly the largest holdings. The fund's structure and expense ratio also play a role in its tracking accuracy and overall returns.

Pharma Innovation

Breakthroughs in pharmaceuticals, a key XLV industry, can significantly boost the fund. Positive clinical trial results or FDA approvals for top holdings like Eli Lilly (LLY) and AbbVie (ABBV) often trigger rallies.

These developments translate to increased investor confidence, driving up stock prices and, consequently, the value of XLV shares. Conversely, setbacks can lead to declines.

Concentrated Holdings

XLV's top holdings, including UnitedHealth Group (UNH) and Johnson & Johnson (JNJ), have a substantial impact due to their high weightings. Sector-specific news, earnings reports, or regulatory changes affecting these companies directly influence the fund's performance.

Because XLV is non-diversified, the fund's returns are more sensitive to the performance of its largest holdings. This concentration can amplify both gains and losses compared to a more diversified fund.

Expense Ratio Impact

XLV's expense ratio, while competitive, impacts net returns over time. The fund's expense ratio is a direct drag on returns, as it reduces the amount of money available for investment.

Investors should consider the expense ratio when evaluating XLV, as it affects the fund's ability to track its index and generate returns. Lower fees generally lead to better long-term performance.

Key insight: Investors should monitor pharmaceutical innovation, the performance of top holdings, and the fund's expense ratio to understand XLV's potential.

Key Metrics for XLV

For XLV, investors should focus on sector concentration, trading costs, and the impact of the fund's replication strategy. These metrics help assess the fund's ability to deliver returns mirroring the healthcare sector.

Holdings Concentration: This metric assesses the distribution of the fund's assets across its holdings. Given XLV's non-diversified status and significant allocation to top holdings like LLY and UNH, a high concentration can amplify both gains and losses. Monitor changes in top holdings' weights, as shifts can indicate evolving sector dynamics.

Tracking Quality: Measures how closely XLV follows its benchmark index's performance. A widening tracking error suggests increased costs or replication challenges. Investors should monitor the tracking difference to ensure the fund effectively mirrors the healthcare sector's returns, net of fees.

Expense Ratio Impact: The expense ratio is a key factor in determining net returns. While not directly provided, monitor the expense ratio to understand its impact on performance. A higher expense ratio can erode returns, especially in periods of low market volatility, making it crucial to assess its competitiveness within the healthcare ETF landscape.

Sector Exposure Shifts: This metric tracks changes in the fund's exposure to different healthcare sub-sectors. As XLV invests in pharmaceuticals, healthcare equipment, and other areas, shifts in allocation can reflect evolving investment strategies. Significant shifts may indicate a change in the fund's risk profile or a response to emerging trends within the healthcare industry.

Trading Volume & Spreads: Assesses the fund's liquidity and trading costs. Wider bid-ask spreads and lower trading volumes can increase transaction costs. Monitor these metrics to gauge the ease of buying and selling shares, especially during periods of market stress, as they directly impact the ETF's tradability.

Volatility Regime: Examines the fund's sensitivity to market volatility. Given the healthcare sector's defensive characteristics, XLV may exhibit lower volatility than broader market indices. Monitor the fund's beta and standard deviation to understand its risk profile and how it reacts to market fluctuations, which is crucial for risk management.

Risk Factors to Monitor

XLV's performance is tied to the health care sector, making it sensitive to industry-specific risks. Concentration in top holdings and regulatory changes pose significant threats to returns.

Concentration in Top Holdings
The fund's performance is significantly influenced by its top holdings, such as Eli Lilly and UnitedHealth Group. Adverse events affecting these companies, including negative clinical trial results or regulatory setbacks, could disproportionately impact the fund's returns. This risk is amplified by the fund's non-diversified nature.
Regulatory and Policy Changes
The healthcare sector is highly susceptible to changes in government regulations and healthcare policy. Shifts in drug pricing, reimbursement rates, or healthcare reform could negatively affect the profitability of the fund's holdings. Unexpected policy announcements or legislative actions could trigger a rapid sell-off in the sector.
Sector-Specific Economic Downturn
A broader economic downturn could lead to reduced healthcare spending, impacting the revenues of companies within the fund. This is especially true if unemployment rises, leading to fewer insured individuals. A decline in elective procedures or a slowdown in pharmaceutical sales would be key triggers.
Biotech and Pharma Volatility
The fund's exposure to biotechnology and pharmaceutical companies introduces volatility due to the inherent risks of drug development and clinical trials. Negative trial results, patent expirations, or unexpected competition can lead to significant price declines. This risk is heightened by the sector's sensitivity to news flow.
Interest Rate Sensitivity
If interest rates rise, the valuations of growth-oriented healthcare companies, which often have high price-to-earnings ratios, could be negatively affected. This is because higher rates make future earnings less valuable in present terms. This risk is particularly relevant if the fund's holdings are perceived as overvalued.
Expense Ratio and Fee Drag
The fund's expense ratio, if not competitive, can erode returns over time. Even small differences in fees can compound over the long term, especially during periods of low market returns. This drag becomes more pronounced if the fund underperforms its benchmark due to other factors.

Frequently Asked Questions

What does the Health Care Select Sector SPDR Fund (XLV) invest in?

XLV aims to mirror the Health Care Select Sector Index. This index includes companies in pharmaceuticals, healthcare equipment and supplies, healthcare providers and services, biotechnology, life sciences tools and services, and healthcare technology. The fund's holdings are therefore concentrated within the healthcare sector.

What is the expense ratio for XLV?

The expense ratio for XLV reflects the annual operating expenses of the fund, expressed as a percentage of assets. This fee covers management and operational costs. Investors should check the fund's prospectus for the most current and precise expense ratio details.

What are the top holdings of XLV?

XLV's top holdings include Eli Lilly and Co, UnitedHealth Group Inc, Johnson & Johnson, AbbVie Inc, and Merck & Co Inc. These top holdings represent a significant portion of the fund's total assets. Reviewing the top holdings can provide insight into the fund's concentration and potential sector exposure.

Is XLV an actively managed or passively managed ETF?

XLV is a passively managed ETF. It seeks to replicate the performance of the Health Care Select Sector Index. This means the fund's holdings and weightings are designed to match the index's composition.

How does XLV compare to other healthcare ETFs?

XLV's performance can be compared to other healthcare ETFs by examining their holdings, expense ratios, and tracking error. Consider the specific index each ETF tracks and the sector weightings. Comparing these factors can help determine which ETF aligns best with an investor's objectives.

What is the historical performance of XLV?

Historical performance data for XLV can be found on financial websites. This data provides insights into the fund's past returns. Investors should remember that past performance does not predict future results.

What are the risks associated with investing in XLV?

Investing in XLV carries risks specific to the healthcare sector, including regulatory changes, drug pricing pressures, and technological advancements. As a sector-specific ETF, XLV may experience higher volatility compared to broader market ETFs. Investors should consider these risks before investing.

How liquid is XLV?

XLV's liquidity is determined by its trading volume and the bid-ask spread. High trading volume typically indicates greater liquidity, making it easier to buy and sell shares. Investors should monitor these factors to assess the ease of trading XLV shares.

What is the structure of XLV?

XLV is structured as an exchange-traded fund (ETF). This structure allows shares to be bought and sold on exchanges throughout the trading day. The fund's structure impacts how it is priced and traded, offering intraday liquidity.

How volatile is XLV?

XLV's volatility is influenced by the healthcare sector's inherent characteristics and market conditions. The fund's price can fluctuate significantly. Investors should assess their risk tolerance and investment horizon when considering XLV.

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage (Top ETF Holdings)

ETF: XLV

0+ articles

Last updated: February 15, 2026

XLV ETF: Investment Factors

Sector Exposure

Holdings Concentration

Expense Considerations

ETF Structure

Trading Liquidity

Investors should consider the bid-ask spread when trading XLV, as wider spreads can increase transaction costs. Monitoring trading volume and spreads can help investors manage trading frictions.

Portfolio Role

Positioning XLV

What Influences XLV?

XLV's performance hinges on the health care sector's outlook, particularly the largest holdings. The fund's structure and expense ratio also play a role in its tracking accuracy and overall returns.

Pharma Innovation

These developments translate to increased investor confidence, driving up stock prices and, consequently, the value of XLV shares. Conversely, setbacks can lead to declines.

Concentrated Holdings

Expense Ratio Impact

XLV's expense ratio, while competitive, impacts net returns over time. The fund's expense ratio is a direct drag on returns, as it reduces the amount of money available for investment.

Investors should consider the expense ratio when evaluating XLV, as it affects the fund's ability to track its index and generate returns. Lower fees generally lead to better long-term performance.

Key insight: Investors should monitor pharmaceutical innovation, the performance of top holdings, and the fund's expense ratio to understand XLV's potential.

Key Metrics for XLV

Risk Factors to Monitor

XLV's performance is tied to the health care sector, making it sensitive to industry-specific risks. Concentration in top holdings and regulatory changes pose significant threats to returns.

Concentration in Top Holdings
The fund's performance is significantly influenced by its top holdings, such as Eli Lilly and UnitedHealth Group. Adverse events affecting these companies, including negative clinical trial results or regulatory setbacks, could disproportionately impact the fund's returns. This risk is amplified by the fund's non-diversified nature.
Regulatory and Policy Changes
The healthcare sector is highly susceptible to changes in government regulations and healthcare policy. Shifts in drug pricing, reimbursement rates, or healthcare reform could negatively affect the profitability of the fund's holdings. Unexpected policy announcements or legislative actions could trigger a rapid sell-off in the sector.
Sector-Specific Economic Downturn
A broader economic downturn could lead to reduced healthcare spending, impacting the revenues of companies within the fund. This is especially true if unemployment rises, leading to fewer insured individuals. A decline in elective procedures or a slowdown in pharmaceutical sales would be key triggers.
Biotech and Pharma Volatility
The fund's exposure to biotechnology and pharmaceutical companies introduces volatility due to the inherent risks of drug development and clinical trials. Negative trial results, patent expirations, or unexpected competition can lead to significant price declines. This risk is heightened by the sector's sensitivity to news flow.
Interest Rate Sensitivity
If interest rates rise, the valuations of growth-oriented healthcare companies, which often have high price-to-earnings ratios, could be negatively affected. This is because higher rates make future earnings less valuable in present terms. This risk is particularly relevant if the fund's holdings are perceived as overvalued.
Expense Ratio and Fee Drag
The fund's expense ratio, if not competitive, can erode returns over time. Even small differences in fees can compound over the long term, especially during periods of low market returns. This drag becomes more pronounced if the fund underperforms its benchmark due to other factors.

Frequently Asked Questions

What does the Health Care Select Sector SPDR Fund (XLV) invest in?

What is the expense ratio for XLV?

What are the top holdings of XLV?

Is XLV an actively managed or passively managed ETF?

How does XLV compare to other healthcare ETFs?

What is the historical performance of XLV?

What are the risks associated with investing in XLV?

How liquid is XLV?

What is the structure of XLV?

How volatile is XLV?

XLV·Health Care Select Sector SPDR Fund

What's happening to XLV today?

News Sentiment Analysis

Recent News Coverage (Top ETF Holdings)

Discover More

XLV ETF: Investment Factors

Sector Exposure

Holdings Concentration

Expense Considerations

ETF Structure

Trading Liquidity

Portfolio Role

Positioning XLV

What Influences XLV?

Pharma Innovation

Concentrated Holdings

Expense Ratio Impact

Key Metrics for XLV

Risk Factors to Monitor

Frequently Asked Questions

News Sentiment Analysis

Recent News Coverage (Top ETF Holdings)

Discover More

XLV ETF: Investment Factors

Sector Exposure

Holdings Concentration

Expense Considerations

ETF Structure

Trading Liquidity

Portfolio Role

Positioning XLV

What Influences XLV?

Pharma Innovation

Concentrated Holdings

Expense Ratio Impact

Key Metrics for XLV

Risk Factors to Monitor

Frequently Asked Questions